NEW YORK (GenomeWeb) – Clontech Laboratories today announced a non-exclusive licensing deal with the Broad Institute for its CRISPR-Cas9 technology.
The deal provides Clontech, a wholly owned subsidiary of Takara Bio, access to the intellectual property surrounding the technology. The US Patent and Trademark Office granted the Broad the first patent for the CRISPR-Cas9 technology earlier this year.
"We believe that CRISPR-Cas9 technology represents a significant improvement over existing genome editing tools, reaching a new level of targeting, efficiency, and in particular ease of use," Clontech General Manager Carol Lou said in a statement. "It is destined to become as valuable and widely utilized as RNAi — perhaps more so."
Financial and other terms of the deal were not disclosed.